<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In 1978, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> and <z:hpo ids='HP_0001909'>Leukemia</z:hpo> Group B initiated a randomized study to determine the usefulness of the addition of <z:chebi fb="0" ids="3139">bleomycin</z:chebi> and/or high-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> to standard therapy for the treatment of certain adult non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Between 1978 and 1985, 177 patients with diffuse large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (DLCL) and 97 patients with other intermediate-grade non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were randomized to receive therapy with three courses of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, adriamycin, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> (CHOP) every 3 weeks with or without low-dose <z:chebi fb="0" ids="3139">bleomycin</z:chebi> by continuous IV infusion </plain></SENT>
<SENT sid="2" pm="."><plain>Responders after three courses were further randomized to 3 weeks of therapy with either high-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (3 gm/m2/week intravenously with leucovorin rescue) or standard-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (30 mg/m2/week orally without rescue) </plain></SENT>
<SENT sid="3" pm="."><plain>Therapy was concluded with three additional courses of CHOP </plain></SENT>
<SENT sid="4" pm="."><plain>Neither the addition of low-dose infusion <z:chebi fb="0" ids="3139">bleomycin</z:chebi> nor the use of high-dose rather than low-dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> had significant effects on response for patients with DLCL; complete response rates for the four treatment programs ranged from 47% to 51% </plain></SENT>
<SENT sid="5" pm="."><plain>Median failure-free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FFS</z:e>) for the entire group of DLCL patients was 12 months; 5-year <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FFS</z:e> was 27% </plain></SENT>
<SENT sid="6" pm="."><plain>There was no significant effect on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FFS</z:e> from the addition of either low-dose <z:chebi fb="0" ids="3139">bleomycin</z:chebi> to CHOP (5-year <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FFS</z:e>: CHOP, 28%; CHOP-B, 26%, P = 0.81), or from the use of different doses of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (5-year <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FFS</z:e>: high-dose, 34%; standard-dose, 33%, P = 0.51) </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with follicular large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, with or without diffuse areas, had a better <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FFS</z:e> (5-year <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FFS</z:e>, 47%) than patients with DLCL (5-year <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FFS</z:e>, 27%), while the patients with the other histopathologic subtypes of diffuse <z:hpo ids='HP_0002665'>lymphomas</z:hpo> had the poorest <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FFS</z:e> (5-year <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FFS</z:e>, 16%) </plain></SENT>
</text></document>